Press Releases July 30, 2026 07:30 AM

SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results

SIGA to provide Q2 2026 business update and financial results call on August 6, 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
SIGA

SIGA Technologies, a commercial-stage pharmaceutical company specializing in infectious disease treatments, has scheduled a webcast and conference call for August 6, 2026, to discuss its second-quarter financial results and provide a business update. The call will be led by CEO Diem Nguyen and CFO Daniel Luckshire, and is accessible via webcast and phone.

SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
SIGA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • SIGA focuses on developing medicines to treat and prevent infectious diseases, particularly orthopoxviruses.
  • The company partners with governments and public health agencies to provide global health countermeasures.
  • Management will discuss Q2 2026 financial results and business updates in the upcoming call.

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 6, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.

Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.

A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 11157253. The archived webcast will be available in the Investor Relations section of the Company's website.

About SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com.

Contact:
Suzanne Harnett
[email protected]


Risks

  • Uncertainty around financial performance and business prospects that will be revealed in the Q2 results.
  • Dependence on governmental and public health contracts which may fluctuate due to policy or funding changes.
  • Challenges inherent in pharmaceutical development and commercialization impacting future growth.

More from Press Releases

Phunware Announces Key Appointments Following Successful HITEC Industry Conference; Expansion of AI Concierge Footprint Jul 30, 2026 20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour Jul 30, 2026 NewGen Provides Update on K25.ai Investment and Strengthened Financial Position Jul 30, 2026 Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer Jul 30, 2026 Safe Pro Successfully Completes U.S. Army Project Convergence Capstone 6 Demonstrating AI-Powered Threat Detection and Mapping Capabilities Utilizing Drone-Based Imagery Jul 30, 2026